Akoya Biosciences, Inc. (AKYA) Bundle
An Overview of Akoya Biosciences, Inc. (AKYA)
General Summary of Akoya Biosciences, Inc. (AKYA)
Akoya Biosciences, Inc. is a life sciences technology company specializing in multiplex imaging and spatial biology solutions. Founded in 2014, the company develops advanced imaging platforms for precision medicine research.
Company Products and Services
- CODEX (Co-Detection by indexing) spatial biology platform
- Phenoptics multiplex immunofluorescence technology
- inForm image analysis software
Financial Performance in Latest Reporting Period
| Financial Metric | 2023 Value |
|---|---|
| Total Revenue | $191.4 million |
| Gross Margin | 62.4% |
| Net Loss | $56.3 million |
Market Position and Industry Leadership
Key Market Segments:
- Oncology research
- Immunology
- Neuroscience
- Translational research
Akoya Biosciences holds a significant market share in spatial biology technology, with approximately 68% of top 50 cancer centers utilizing their platforms.
| Market Metrics | 2024 Data |
|---|---|
| Total Addressable Market | $3.2 billion |
| Market Growth Rate | 22.5% |
| Global Research Installations | Over 500 institutions |
Mission Statement of Akoya Biosciences, Inc. (AKYA)
Mission Statement of Akoya Biosciences, Inc. (AKYA)
Akoya Biosciences, Inc. mission statement focuses on advancing precision medicine through multiplex tissue imaging technologies.
Core Components of Mission Statement
| Component | Specific Details | Quantitative Metrics |
|---|---|---|
| Technological Innovation | Advanced multiplex imaging platforms | 4 proprietary imaging technologies |
| Research Support | Enabling comprehensive tissue analysis | Over 1,200 published research papers using Akoya technologies |
| Clinical Applications | Precision medicine diagnostic solutions | Utilized in 250+ clinical research institutions |
Technological Capabilities
- CODEX® Digital Spatial Profiling platform
- Phenoptics™ Multispectral Imaging Solution
- inForm® Tissue Analysis Software
- PhenoImager™ High-Throughput Imaging Platform
Market Performance Metrics
| Financial Indicator | 2023 Value |
|---|---|
| Total Revenue | $136.4 million |
| Research & Development Expenses | $62.3 million |
| Number of Patents | 87 issued patents |
Research Impact
Key Research Domains:
- Oncology tissue analysis
- Immunology research
- Neuroscience imaging
- Rare disease diagnostics
Global Research Collaborations
| Collaboration Type | Number of Partnerships |
|---|---|
| Academic Institutions | 78 active partnerships |
| Pharmaceutical Companies | 42 ongoing collaborations |
| Cancer Research Centers | 31 active research programs |
Vision Statement of Akoya Biosciences, Inc. (AKYA)
Vision Statement Components of Akoya Biosciences, Inc. (AKYA)
Precision Oncology Technology LeadershipAkoya Biosciences focuses on advanced multiplex immunofluorescence (mIF) and immunohistochemistry (IHC) technologies. As of Q4 2023, the company's precision oncology platform enables spatial biology research with the following key metrics:
| Technology Platform | Performance Metrics |
|---|---|
| CODEX® Platform | Up to 50 biomarkers per tissue section |
| Phenoptics™ Platform | High-resolution cellular analysis capabilities |
Market positioning reflects strategic objectives in spatial biology and oncology research:
- Total addressable market for spatial biology: $3.8 billion by 2027
- Current research customer base: 350+ academic and pharmaceutical institutions
- Annual revenue in precision oncology technologies: $84.2 million (2023)
Innovation metrics demonstrating technological advancement:
| R&D Investment | 2023 Metrics |
|---|---|
| Research & Development Expenses | $42.6 million |
| New Patent Applications | 7 filed in 2023 |
Scientific publication and collaboration metrics:
- Peer-reviewed publications utilizing Akoya technologies: 500+
- International research collaborations: 45 active partnerships
- Citations of Akoya platform research: 2,300+ in 2023
Core Values of Akoya Biosciences, Inc. (AKYA)
Core Values of Akoya Biosciences, Inc. (AKYA)
Innovation and Scientific Excellence
Akoya Biosciences demonstrates commitment to innovation through substantial R&D investments. In fiscal year 2023, the company allocated $45.2 million toward research and development, representing 31.4% of total revenue.
| R&D Metric | 2023 Data |
|---|---|
| R&D Expenditure | $45.2 million |
| R&D as % of Revenue | 31.4% |
Customer-Centric Approach
Akoya Biosciences prioritizes customer satisfaction through targeted support strategies.
- Net Promoter Score (NPS): 72
- Customer retention rate: 94.3%
- Average customer support response time: 2.1 hours
Commitment to Scientific Integrity
The company maintains rigorous scientific standards across its product development processes.
| Integrity Metric | 2023 Performance |
|---|---|
| Published Peer-Reviewed Papers | 37 |
| Clinical Validation Studies | 12 |
Collaborative Environment
Akoya Biosciences fosters collaboration through strategic partnerships and internal initiatives.
- Academic Collaborations: 18
- Industry Partnerships: 9
- Internal Cross-Functional Teams: 22
Sustainability and Ethical Practices
The company integrates sustainability into its operational framework.
| Sustainability Metric | 2023 Data |
|---|---|
| Carbon Emission Reduction | 15.7% |
| Renewable Energy Usage | 42% |
Akoya Biosciences, Inc. (AKYA) DCF Excel Template
5-Year Financial Model
40+ Charts & Metrics
DCF & Multiple Valuation
Free Email Support
Disclaimer
All information, articles, and product details provided on this website are for general informational and educational purposes only. We do not claim any ownership over, nor do we intend to infringe upon, any trademarks, copyrights, logos, brand names, or other intellectual property mentioned or depicted on this site. Such intellectual property remains the property of its respective owners, and any references here are made solely for identification or informational purposes, without implying any affiliation, endorsement, or partnership.
We make no representations or warranties, express or implied, regarding the accuracy, completeness, or suitability of any content or products presented. Nothing on this website should be construed as legal, tax, investment, financial, medical, or other professional advice. In addition, no part of this site—including articles or product references—constitutes a solicitation, recommendation, endorsement, advertisement, or offer to buy or sell any securities, franchises, or other financial instruments, particularly in jurisdictions where such activity would be unlawful.
All content is of a general nature and may not address the specific circumstances of any individual or entity. It is not a substitute for professional advice or services. Any actions you take based on the information provided here are strictly at your own risk. You accept full responsibility for any decisions or outcomes arising from your use of this website and agree to release us from any liability in connection with your use of, or reliance upon, the content or products found herein.